Company profile
Denali Therapeutics Inc.
NASDAQ: DNLI · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
52DFH 55DQ 61GM 15SS 71
v0.1 · 65/100 weight · provisional
↑ market scale, balance-sheet leverage · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$512.5M
Employees
503
as of 2026-08-07
Market cap
$3.9B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$512.5M-$512.5M2025
Operating income-$555.3M-$555.3M2025
Total assets$1.1B$1.1B2025
Liabilities$131.1M$131.1M2025
Equity$1.0B$1.0B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2020
By product
Alzheimer's Disease Services100%
By geography
Not disclosed.
The read
What is Denali Therapeutics Inc.’s revenue?
Denali Therapeutics Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Praxis Precision Medicines, Inc.61COruka Therapeutics, Inc.66BScholar Rock Holding Corporation39DViking Therapeutics, Inc.69BAmylyx Pharmaceuticals, Inc.51DSELLAS Life Sciences Group, Inc.50DNeighbors
San Mateo →Key facts
CEORyan J. Watts
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: DNLI
Employees503
IPO date2017-12-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.